• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bristol-Myers Squibb, Duke Clinical Research Institute collaborate

Bristol-Myers Squibb, Duke Clinical Research Institute collaborate

June 25, 2014
CenterWatch Staff

Bristol-Myers Squibb is collaborating with Duke University through its Duke Clinical Research Institute (DCRI), focusing on clinical trial transparency. BMS will expand access to a broader set of clinical trial information from in-scope, company-sponsored studies and enable an independent scientific review through DCRI of requests from researchers that meet pre-specified requirements.

The collaboration with DCRI is one of a series of initiatives by Bristol-Myers Squibb to support data sharing and enhance the company’s existing policies on transparency and disclosure of clinical trial information. Clinical trial information being made available for scientific research will include protocols, full clinical study reports (CSR) and de-identified, patient-level data and study-level data for medicines and indications approved in the U.S. and/or Europe for trials completed after January 2008. Information from terminated programs will be available two years after discontinuation.

“Bristol-Myers Squibb’s collaboration with DCRI reflects our commitment to providing broader, more timely access to important clinical trial information and serves as a catalyst to strengthening public confidence in medicines, advancing science and improving public health,” said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, BMS.

BMS also will publish CSR synopses at http://bms.com/clinical_trials/ for studies that support a product’s marketing authorization application to the FDA or the EMA shortly after the regulatory approval of the product has been granted. The company also has committed to provide lay-language summaries of clinical trial results for patients who participated in clinical trials and wish to receive a summary of the aggregate study level results. BMS is working with various industry groups and regulators to evaluate the most effective method to deliver this level of detail to patients.

DCRI faculty members will be an independent scientific review committee to evaluate data requests and their accompanying research proposals from qualified scientific and medical researchers seeking access to clinical trial information from BMS-sponsored trials, and make final decisions on data sharing. Proposals will be evaluated based on the scientific rationale for the research as well as plans for statistical analyses and publication.

BMS’ existing policy on disclosure of clinical trial information includes registration of all phase I, II, III and IV interventional trials in which BMS has responsibility, and open and timely reporting of results, regardless of outcome, from sponsored clinical trials involving BMS marketed products through scientific congresses or publication in peer-reviewed journals.

BMS’ policy on data sharing is aligned with the Principles for Responsible Clinical Trial Data Sharing released by the U.S. and European pharmaceutical trade associations, PhRMA and EFPIA, by which biopharmaceutical companies pledge their commitment to enhancing public health through responsible sharing of clinical trial data consistent with safeguarding patient privacy and informed consent, respecting the integrity of national regulatory systems and maintaining incentives for investment in biomedical research.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing